Abatacept treatment for autoimmune hemolytic anemia occurring post hematopoietic stem cell transplantation
Por:
Gabelli M, Pérez-Martínez A, Bueno Sánchez D, Lucchini G, Grenier LP, Couture F, Limerick E, Bernaud V, Trabazo-del Castillo M and Ngwube A
Publicada:
1 feb 2024
Ahead of Print:
1 dic 2023
Resumen:
Filiaciones:
Gabelli M:
Bone Marrow Transplantation, Great Ormond Street Hospital for Children, London, United Kingdom
Pediatric Hematology, Oncology and Stem Cell Transplantation, Università degli Studi di Padova, Padova, Italy
Pérez-Martínez A:
Pediatric Hematology, Oncology and Stem Cell Transplantation, Hospital Universitario La Paz, Universidad Autónoma de Madrid, Instituto de Investigación La Paz, Madrid, Spain
Bueno Sánchez D:
Pediatric Hematology, Oncology and Stem Cell Transplantation, Hospital Universitario La Paz, Universidad Autónoma de Madrid, Instituto de Investigación La Paz, Madrid, Spain
Grenier LP:
Bone Marrow Transplantation, CHU de Québec-Université Laval, Hotel-Dieu de Québec, Québec, Canada
Couture F:
Bone Marrow Transplantation, CHU de Québec-Université Laval, Hotel-Dieu de Québec, Québec, Canada
Limerick E:
Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
Bernaud V:
Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, USA
Trabazo-del Castillo M:
Pediatric Hematology, Oncology and Stem Cell Transplantation, Hospital Sant Joan de Déu, Barcelona, Spain
Ngwube A:
Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, USA
|